Clinical Trial Update: Mirdametinib in Histiocytic Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mirdametinib for histiocytic disorders including Langerhans cell histiocytosis, Juvenile xanthogranuloma, and Rosai-Dorfman di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Xanthogranuloma
• Langerhans Cell Histiocytosis
• Rosai-dorfman Disease

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG) | Phase 2 | Status: RECRUITING